Lysophosphatidylcholine--biomarker of Metformin action: studied using UPLC/MS/MS.

An UPLC/MS/MS based metabonomic method was developed and applied to the elucidation of biomarker of metformin action. The plasma metabolite profiling in healthy volunteers before and after per os metformin was determined with UPLC/MS/MS and analyzed by using multivariate statistics. Significant difference in endogenous metabolite profiles was revealed before and after administration of metformin. Four biomarkers found were lysophosphatidylcholines (LPCs), and their structures were tentatively identified to be 16:0 LPC, 18:0 LPC, 18:1 LPC and 18:2 LPC according to the molecular ions information and corresponding fragments of product ion scan. Lysophosphatidylcholine in blood may be involved in metformin treatment.

[1]  J. Schölmerich,et al.  Metformin reduces cellular lysophosphatidylcholine and thereby may lower apolipoprotein B secretion in primary human hepatocytes. , 2008, Biochimica et biophysica acta.

[2]  R. Norman,et al.  Metformin in polycystic ovary syndrome: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[3]  R. DeFronzo,et al.  Metformin: A review of its metabolic effects , 1998 .

[4]  J. Lindon,et al.  Metabonomics: a platform for studying drug toxicity and gene function , 2002, Nature Reviews Drug Discovery.

[5]  Eric Yang,et al.  A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition. , 2005, Rapid communications in mass spectrometry : RCM.

[6]  J. Lindon,et al.  NMR‐based metabonomic approaches for evaluating physiological influences on biofluid composition , 2005, NMR in biomedicine.

[7]  Samy I McFarlane,et al.  Metformin: An Update , 2002, Annals of Internal Medicine.

[8]  M. Reily,et al.  Metabonomics: evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[9]  I. Wilson,et al.  A combined (1)H NMR and HPLC-MS-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. , 2005, Journal of pharmaceutical and biomedical analysis.

[10]  I. Wilson,et al.  Gut microorganisms, mammalian metabolism and personalized health care , 2005, Nature Reviews Microbiology.

[11]  Elaine Holmes,et al.  The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. , 2005, Pharmacogenomics.

[12]  D. Moher,et al.  WITHDRAWN: Metformin monotherapy for type 2 diabetes mellitus. , 2015, The Cochrane database of systematic reviews.

[13]  I. Wilson,et al.  Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. , 2007, Journal of proteome research.

[14]  Qing Yang,et al.  Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[15]  Guowang Xu,et al.  Structural identification of human blood phospholipids using liquid chromatography/quadrupole-linear ion trap mass spectrometry , 2004 .

[16]  Jianren Gu,et al.  Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. , 2005, Analytical chemistry.

[17]  Ping Liu,et al.  Metabonomic study of aristolochic acid-induced nephrotoxicity in rats. , 2006, Journal of proteome research.